Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors

NCT02616211 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02616211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02616211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Completed
Start date
October 31, 2014
Completion date
December 31, 2019
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of lung, alk genes, cancer of lung, egfr genes, lung cancer, lung neoplasm, pulmonary cancer